Overview
Sponsor-declared trial summary
Atherosclerotic Cardiovascular Disease (ASCVD)
To evaluate whether muvalaplin is superior to placebo in reducing the risk of the composite endpoint of MACE-4.
Key facts
- Sponsor
- Eli Lilly & Co.
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 24 Apr 2026 → ongoing
- Decision date (initial)
- 2025-10-20
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
External identifiers
- EU CT number
- 2025-521067-13-00
- WHO UTN
- U1111-1322-3786
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Safety, Pharmacogenomic, Pharmacodynamic, Therapy, Efficacy, Pharmacoeconomic, Pharmacokinetic
To evaluate whether muvalaplin is superior to placebo in reducing the risk of the composite endpoint of MACE-4.
Conditions and MedDRA coding
Atherosclerotic Cardiovascular Disease (ASCVD)
Regulatory references
- Scientific advice from competent authorities
- European Medicines Agency
- Plan to share IPD
- Yes
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 2
- Have Lp(a) levels of 175 nmol/L or higher
- Meet one of the following criteria: • Have had a previous heart-related event, such as a heart attack, stroke, or a procedure to restore blood flow to the heart or other parts of the body • Be at risk for a first heart-related event, defined by one or more of the following: • Coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a previous heart-related event • A high coronary artery calcium (CAC) score • Reduced kidney function with diabetes • Combination(s) of high risk factors
Exclusion criteria 6
- Have had a major heart or blood vessel event within 90 days before screening
- Be planning any heart or artery surgery
- Have very high blood pressure or have serious heart failure
- Have had or planning to have a procedure to remove cholesterol from the blood within 90 days of screening
- Have severe kidney failure
- Have a history of cancer within 5 years before screening
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 1
- Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 1
PRD12097099 · Product
- Active substance
- Muvalaplin
- Substance synonyms
- LY3473329, (2S,2'S,2''S)-3,3',3''-((nitrilotris(methylene))tris(benzene-3,1-diyl))tris(2-((R)-pyrrolidin-3-yl)propanoic acid)
- Pharmaceutical form
- TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 0 Other
- Max total dose
- 0 Other
- Max treatment duration
- 63 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- ELI LILLY AND COMPANY LIMITED
- Paediatric formulation
- No
- Orphan designation
- No
Placebo 1
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Eli Lilly & Co.
- Sponsor organisation
- Eli Lilly & Co.
- Address
- 1 Lilly Corporate Center
- City
- Indianapolis
- Postcode
- 46285-0001
- Country
- United States
Scientific contact point
- Organisation
- Eli Lilly & Co.
- Contact name
- Lilly Clinical Trials information desk
Public contact point
- Organisation
- Eli Lilly & Co.
- Contact name
- Lilly Clinical Trials information desk
Third parties 17
| Organisation | City, country | Duties |
|---|---|---|
| LabCorp Drug Development, Inc. ORL-000014850
|
Meyrin/Geneva, Switzerland | Laboratory analysis |
| Labcorp Pharmaceutical Research And Development (Shanghai) Co. Ltd. ORG-100043119
|
Shanghai, China | Laboratory analysis |
| Icon (Lr) Limited ORG-100042612
|
Dublin 18, Ireland | Other |
| Bioagilytix Labs LLC ORG-100013030
|
Durham, United States | Laboratory analysis |
| Trialbee AB ORG-100051369
|
Malmo, Sweden | Other |
| Greenphire LLC ORG-100041621
|
King Of Prussia, United States | Other |
| Labcorp Development (Asia) Pte Ltd ORG-100050418
|
Singapore, Singapore | Laboratory analysis |
| Iqvia Biotech LLC ORG-100008704
|
Durham, United States | On site monitoring |
| Labcorp Early Development Laboratories Inc. ORG-100012865
|
Madison, United States | Laboratory analysis |
| Veeva Systems Inc. ORG-100006053
|
Pleasanton, United States | Data management |
| Pharmaserve Lilly S.A.C.I. ORG-100005347
|
Kifisia, Greece | On site monitoring, Code 12, Other, Code 2, Code 5 |
| RWS Life Sciences Inc. ORG-100042348
|
East Hartford, United States | Other |
| Cleveland Clinic Foundation ORG-100028017
|
Cleveland, United States | Code 11 |
| Icon Clinical Research Limited ORG-100008322
|
Dublin 18, Ireland | Other |
| Labcorp Central Laboratory Services LP ORG-100032236
|
Indianapolis, United States | Laboratory analysis |
| Labcorp Pharmaceutical Research And Development (Shanghai) Co. Ltd. ORG-100043119
|
Shanghai, China | Laboratory analysis |
| Clariness GmbH ORG-100045306
|
Hamburg, Germany | Other |
Locations
14 EU/EEA countries · 279 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Ongoing, recruitment ended | 220 | 18 |
| Belgium | Ongoing, recruitment ended | 205 | 21 |
| Czechia | Ongoing, recruitment ended | 130 | 17 |
| Denmark | Ongoing, recruitment ended | 50 | 3 |
| France | Ongoing, recruitment ended | 105 | 16 |
| Germany | Ongoing, recruitment ended | 550 | 40 |
| Greece | Ongoing, recruitment ended | 145 | 11 |
| Hungary | Ongoing, recruitment ended | 125 | 15 |
| Italy | Ongoing, recruitment ended | 130 | 17 |
| Netherlands | Ongoing, recruitment ended | 215 | 19 |
| Poland | Ongoing, recruitment ended | 205 | 21 |
| Romania | Ongoing, recruitment ended | 175 | 25 |
| Slovakia | Ongoing, recruitment ended | 115 | 13 |
| Spain | Ongoing, recruitment ended | 790 | 43 |
| Rest of world
Argentina, India, Australia, United Kingdom, Canada, Taiwan, Brazil, United States, China, Korea, Republic of, Mexico, Japan
|
— | 7,290 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Austria | 2025-10-22 | 2025-11-12 | 2026-03-27 | ||
| Belgium | 2025-10-21 | 2025-11-03 | 2026-03-27 | ||
| Czechia | 2025-10-14 | 2025-10-30 | 2026-03-27 | ||
| Denmark | 2025-11-05 | 2025-11-10 | 2026-03-27 | ||
| France | 2025-11-03 | 2025-11-20 | 2026-03-27 | ||
| Germany | 2025-10-16 | 2025-10-28 | 2026-03-27 | ||
| Greece | 2025-12-18 | 2025-12-22 | 2026-03-27 | ||
| Hungary | 2025-10-22 | 2025-11-10 | 2026-03-27 | ||
| Italy | 2025-10-24 | 2025-11-04 | 2026-03-27 | ||
| Netherlands | 2025-11-11 | 2025-12-18 | 2026-03-27 | ||
| Poland | 2025-10-23 | 2025-11-04 | 2026-03-27 | ||
| Romania | 2025-10-22 | 2025-11-07 | 2026-03-27 | ||
| Slovakia | 2025-10-13 | 2025-10-28 | 2026-03-27 | ||
| Spain | 2025-10-24 | 2025-11-04 | 2026-03-27 |
Oversight and notifications
Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77
Temporary halts 14 · Art. 38 CTR
Temporary halt TH-128578
- Halt date
- 2026-03-27
- Member states concerned
- Denmark
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128582
- Halt date
- 2026-03-27
- Member states concerned
- Germany
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128592
- Halt date
- 2026-03-27
- Member states concerned
- Spain
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128584
- Halt date
- 2026-03-27
- Member states concerned
- Greece
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128594
- Halt date
- 2026-03-27
- Member states concerned
- Netherlands
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128572
- Halt date
- 2026-03-27
- Member states concerned
- Austria
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128586
- Halt date
- 2026-03-27
- Member states concerned
- Hungary
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128596
- Halt date
- 2026-03-27
- Member states concerned
- Poland
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128574
- Halt date
- 2026-03-27
- Member states concerned
- Belgium
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128588
- Halt date
- 2026-03-27
- Member states concerned
- Italy
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128598
- Halt date
- 2026-03-27
- Member states concerned
- Slovakia
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128576
- Halt date
- 2026-03-27
- Member states concerned
- Czechia
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128580
- Halt date
- 2026-03-27
- Member states concerned
- France
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Temporary halt TH-128590
- Halt date
- 2026-03-27
- Member states concerned
- Romania
- Publication date
- 2026-04-10
- Reason
- Study management related
- Benefit-risk balance changed
- No
- Treatment stopped
- No
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 295 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_Protocol 2025-521067-13-00_redacted | a |
| Protocol (for publication) | D1_Protocol_2025-521067-13-00_GR_Redacted | a |
| Protocol (for publication) | D4_Study Participant Contact Card_GR | 1 |
| Recruitment arrangements (for publication) | 1_Recruitment and Informed consent procedure_GR | 1 |
| Recruitment arrangements (for publication) | K1_Appreciation Items | 1 |
| Recruitment arrangements (for publication) | K1_List of participating sites | 1 |
| Recruitment arrangements (for publication) | K1_List of sites_Redacted | 3 |
| Recruitment arrangements (for publication) | K1_Lp a-Infographic_Master | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment and consenting procedure | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment and ICF form | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment and informed consent procedure | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment and Informed consent procedure | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment and Informed consent procedure | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment and Informed consent procedure | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Complete Consent Security and Privacy Quick Reference Guide_Redacted | 1.5 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_eConsent Submission Letter ENG | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_FRA | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Getting Started Patient facing landing page_Redacted | 1.1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_IQVIA Complete Consent Security and Privacy QRG_BEDU_Redacted | 1.5 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_IQVIA Complete Consent Security and Privacy QRG_BEFR_Redacted | 1.5 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_IQVIA Complete Consent Security and Privacy QRG_ENG_Redacted | 1.5 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_List of Sites | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Meclinas Carousel Post Images_Redacted | 4.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Meclinas Flyer_Redacted | 4.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Meclinas Images | 2.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Meclinas Recruitment Strategy_Redacted | 5.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Meclinas Slogans_Redacted | 4.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Arrangements_Participant Facing Screenshots_Redacted | 1.4 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_PL | 1.0 |
| Recruitment arrangements (for publication) | K1_Recruitment Procedure | 1.1 |
| Recruitment arrangements (for publication) | K1_recruitment texts_variant 1_FutureMeds GmbH_Site Berlin | 1.1 |
| Recruitment arrangements (for publication) | K1_recruitment texts_variant 1_FutureMeds GmbH_Site Offenbach_DE_v1 1 | 1.1 |
| Recruitment arrangements (for publication) | K1_recruitment texts_variant 2_FutureMeds GmbH_Site Berlin_DE_v1 1 | 1 |
| Recruitment arrangements (for publication) | K1_recruitment texts_variant 2_FutureMeds GmbH_Site Offenbach | 1.1 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_Dr to patient letter_redacted | 1.1 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_flyer | 1.1 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_poster | 1.1 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_recruitment brochure_redacted | 1.1 |
| Recruitment arrangements (for publication) | K2_ Recruitment material_referral letter_redacted | 1.1 |
| Recruitment arrangements (for publication) | K2_Brochure_Master_RO_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_EKBG_Brochure_Master_ES_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_EKBG_Flyer_Master_ES | 1.0 |
| Recruitment arrangements (for publication) | K2_EKBG_Letter-Doctor-Referral_Master_ES_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_EKBG_Letter-Doctor-to-Patient_Master_ES_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_EKBG_Poster_Master_ES | 1.0 |
| Recruitment arrangements (for publication) | K2_Flyer_Master_RO | 1 |
| Recruitment arrangements (for publication) | K2_Letter-Doctor-Referral_Master_RO_Redacted | 2 |
| Recruitment arrangements (for publication) | K2_Letter-Doctor-to-Patient_Master_RO_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Poster_Master_RO | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Arrangments_Meclinas Website Text_BEDU_Redacted | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material Brochure_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Appreciation Items | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_BEDU_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_BEFR_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_GR_Redacted | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_IT Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Master_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Brochure_Master_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Redacted | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Brochure_Redacted | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Doctor Referral Letter_FRA_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Doctor to Patient Letter_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Doctor-to-Patient_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_EKBG_Brochure_Master_PL_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_EKBG_Flyer_Master_PL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_EKBG_Letter Doctor to Patient_Master_PL_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_EKBG_Letter Participant Welcome_Master_PL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_EKBG_Poster_Master_PL | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Flyer_FRA | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_GR | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_IT | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Flyer_Master | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_For Advertisement_Werbetext | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Infographic | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor Referral_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor Referral_Site facing_BEDU_Redacted | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor Referral_Site facing_BEFR_Redacted | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to Patient_GR_Redacted | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to Patient_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to Patient_Subject facing_BEDU_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Doctor to Patient_Subject facing_BEFR_Redacted | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter Participant Welcome | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Letter-Doctor-Referral_Redacted | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter-Doctor-to-Patient_Master_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Letter-Doctor-to-Patient_Redacted | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Lp_a infographic | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Lpa Infographic | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Lpa Infographic | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Lpa Infographic_Comparison report | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Lpa-Infographic BEDU | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Lpa-Infographic BEFR | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Lpa-Infographic_Master | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Meclinas Website Text_BEDU_Redacted | 2.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_BEDU | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_BEFR | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Poster_FRA | 1.0 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_GR | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_IT | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Poster_Master | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Material_Prescreening Tool Questions | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Campaign Ads | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Recruitment Campaign Link2Trials | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_site IMED | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_site KF | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Study Calendar 2025 | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment material_Study Calendar 2026 | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Flyer_Master | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment Materials_Poster-Master | 1 |
| Recruitment arrangements (for publication) | K3_Recruitment material Letter-Doctor-To-Patient_Redacted | 1 |
| Recruitment arrangements (for publication) | K4_Recruitment arrangments_Informed consent and patient recruitment procedure_PL | 1.0 |
| Recruitment arrangements (for publication) | K4_Recruitment material Flyer | 1 |
| Recruitment arrangements (for publication) | K5_Recruitment material Poster | 1 |
| Recruitment arrangements (for publication) | K6_Other subject information material eConsent - Participant-Facing Screenshots_Redacted | 1.4 |
| Recruitment arrangements (for publication) | K6_Other subject information material eConsent Patient-facing landing page_Redacted | 1.1 |
| Recruitment arrangements (for publication) | K6_Other subject information material eConsent Submission Letter | 1 |
| Recruitment arrangements (for publication) | K6_Sanos Site-Specific Recruitment Material | 1.1 |
| Subject information and informed consent form (for publication) | L1_ SIS and ICF_Addendum Genetic_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_ SIS and ICF_Addendum optional research PK_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_ SIS and ICF_Addendum Pre-screening_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_ SIS and ICF_Main ICF Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_ICF_Main_GR_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Main ICF_RO_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Optional Activity ICF_RO_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_Prescreening ICF_GR | 1 |
| Subject information and informed consent form (for publication) | L1_Prescreening ICF_RO | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Main_Redacted | 2.3 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF Pre-Screening_Redacted | 1.4 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Addendum Optional Activity_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Addendum Prescreening | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Addendum Prescreening_TC | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Confidentiality Notice for TLC | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_DPA | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_DPA | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Genetic Addendum_FRA_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_BEDU_redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_BEFR_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_ENG_redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_FRA | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_FRA_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main ICF_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Main_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activities Consent_BEDU_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activities Consent_BEFR_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activities Consent_ENG_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activity Addendum_FRA | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activity Addendum_FRA_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activity Addendum_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional activity ICF_redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Activity_PK_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Optional Genetic research | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PL_Main ICF_EKBG_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PL_Optional Activity ICF_EKBG_Redacted | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_PL_Prescreening ICF_EKBG_Unapplied | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pre-screening ICF | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pre-screening ICF_Redacted | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pre-screening ICF_redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnancy Addendum_FRA_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant participant ICF | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner Consent | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant Partner Form | 1.0 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Pregnant partner ICF | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Prescreening | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Prescreening Addendum_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Prescreening ICF | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and Prescreening ICF_BEDU | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and Prescreening ICF_BEFR | 1.2 |
| Subject information and informed consent form (for publication) | L1_SIS and Prescreening ICF_ENG | 1.2 |
| Subject information and informed consent form (for publication) | L1_Study Participants Pregnant Partner | 1.1 |
| Subject information and informed consent form (for publication) | L1_Study Participants_Pregnant Partner | 1.0 |
| Subject information and informed consent form (for publication) | L2_Compensation Information Sheet_RO | 3 |
| Subject information and informed consent form (for publication) | L2_Confidentiality Company Information Notice | 1 |
| Subject information and informed consent form (for publication) | L2_List of ssICF contact details_Redacted | 3 |
| Subject information and informed consent form (for publication) | L2_Other subject info material_Patient Info Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject info_ MOVE LPa_Participant_Newsletter_Edition01 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject info_ MOVE LPa_Participant_Newsletter_Edition02 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject info_ MOVE LPa_Participant_Newsletter_Edition03 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject info_ MOVE LPa_Participant_Newsletter_Edition04 | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material Emergency Card EKBG_Poland | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material Leaflet on trial subject rights | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Care Partner Guide_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Compensation Information Sheet_Redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Confidentiality Company Information Notice_GR | 2 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Confidentiality Notice | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_ConneX Travel Contact Card_GR_Redacted | 10 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_ConneX Travel Reference Guide for Participants_GR_Redacted | 10 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_e-Consent Participant-Facing Screenshots_BEDU_Redacted | 1.4 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_e-consent Participant-Facing Screenshots_BEFR_Redacted | 1.4 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_e-Consent Participant-Facing Screenshots_ENG_Redacted | 1.4 |
| Subject information and informed consent form (for publication) | L2_Other Subject information material_ICF_Sponsor_Statement_ENG_Redacted | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_IQVIA eConsent Privacy Policy_BEDU | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_IQVIA eConsent Privacy Policy_BEFR | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_IQVIA eConsent Privacy Policy_ENG | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Letter Participant Welcome_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Lp a Infographic_GR | 2.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient card | 1.0 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient Emergency Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Patient Newsletter_Issue 1_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Patient Newsletter_Issue 2_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Patient Newsletter_Issue 3_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Patient Newsletter_Issue 4_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient-facing landing page_BEDU_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient-facing landing page_BEFR_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Patient-facing landing page_ENG_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Privacy Policy eConsent_Redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Calendar 2025_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Calendar 2026_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Calendar 2027 | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Calendar 2027_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Calendar 2028 | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Calendar 2028_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Calendar 2029 | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Calendar 2029_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Calendar 2030 | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Calendar 2030_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Calendar Magnet | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Calendar Magnet_GR | 2.1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Guide Master_GR_Redacted | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Guide_Redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Medicine Reminder Card_GR_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Medicine Reminder Card_Redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Study Medicine Reminder Magnet_GR_Redacted | 2.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Study Medicine Reminder Magnet_redacted | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Thank You End Of Study_Master_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Thank You Participation_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Thank You Screening_GR | 1.1 |
| Subject information and informed consent form (for publication) | L2_Other subject information material_Visit Card | 1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information Material_Visit Card Noname_Master_GR | 2.1 |
| Subject information and informed consent form (for publication) | L2_Other Subject Information_Patient Card | 1.0 |
| Subject information and informed consent form (for publication) | L2_Study Participant Contact Card_GR | 1 |
| Subject information and informed consent form (for publication) | L2_Study Participant Contact Card_Romania | 1 |
| Subject information and informed consent form (for publication) | L2_Subject information material_eConsent Submission Letter_Eli Lilly - J2O-MC-EKBG_Italy | 4.0 |
| Subject information and informed consent form (for publication) | L2_Subject information material_IQVIA Complete Consent Security and Privacy Quick Reference Guide | 1.5 |
| Subject information and informed consent form (for publication) | L2_Subject information material_IQVIA E2E Privacy Policy | 1.0 |
| Subject information and informed consent form (for publication) | L2_Subject information material_IQVIA Getting Started Patient-facing landing page | 1.1 |
| Subject information and informed consent form (for publication) | L2_Subject information material_Notification Letter IQVIA complete consent platform update | 1 |
| Subject information and informed consent form (for publication) | L2-Subject information material_IQVIA Complete Consent - Participant-Facing Screenshots | 1.4 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_ Study-Medicine-Reminder-Card_Redacted | 2 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Brochure_Redacted | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Flyer | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Letter-Doctor-to-Patient_Redacted | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Lp a -Infographic | 2 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Poster | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Calendar-2025 | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Calendar-2026 | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Calendar-2027 | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Calendar-2028 | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Calendar-2029 | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Calendar-2030 | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Calendar-Magnet | 2 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Guide_Redacted | 1 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Study-Medicine-Reminder-Magnet_Redacted | 2 |
| Subject information and informed consent form (for publication) | L3_Other subject information material_Visit-Card-Noname | 2 |
| Subject information and informed consent form (for publication) | L3_Patient card_master | 1 |
| Subject information and informed consent form (for publication) | L3_patient contact card | 2 |
| Subject information and informed consent form (for publication) | L4_Compensation Information Sheet_EKBG_PL | 1.0 |
| Subject information and informed consent form (for publication) | L5_Info Re insurance Conditions for Patient | 1.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis _NL_2025-521067-13-00_Redacted | 2.0 |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis 2025-521067-13-00 IT _Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis EN 2025-521067-13-00_ro-ROM_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2025-521067-13-00_GR_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_2025-521067-13-00_PL_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_AT_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_BEDU_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_BEFR_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_BEGE_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_CZ_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_ENG_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol synopsis_ES_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_FRA_2025-521067-13-00_Redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_HU_2025-521067-13-00_redacted | a |
| Synopsis of the protocol (for publication) | D1_Protocol Synopsis_SK_Redacted | a |
Application history
19 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2025-06-20 | Germany | Acceptable 2025-10-13
|
2025-10-13 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2025-10-21 | Acceptable 2025-10-13
|
2025-10-21 | |
| 3 | SUBSTANTIAL MODIFICATION | SM-1 | 2025-10-22 | Acceptable | 2025-10-23 | |
| 4 | SUBSTANTIAL MODIFICATION | SM-2 | 2025-10-24 | Acceptable | 2025-11-24 | |
| 5 | SUBSTANTIAL MODIFICATION | SM-4 | 2025-11-12 | Acceptable | 2026-01-29 | |
| 6 | SUBSTANTIAL MODIFICATION | SM-3 | 2025-11-14 | Germany | Acceptable | 2026-02-04 |
| 7 | SUBSTANTIAL MODIFICATION | SM-7 | 2026-01-30 | Acceptable | 2026-03-16 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-8 | 2026-02-06 | Acceptable | 2026-02-20 | |
| 9 | SUBSTANTIAL MODIFICATION | SM-5 | 2026-02-11 | Acceptable | 2026-03-23 | |
| 10 | SUBSTANTIAL MODIFICATION | SM-9 | 2026-02-11 | Germany | Acceptable | 2026-04-02 |
| 11 | SUBSTANTIAL MODIFICATION | SM-6 | 2026-02-19 | Acceptable | 2026-04-16 | |
| 12 | SUBSTANTIAL MODIFICATION | SM-10 | 2026-02-24 | Acceptable | 2026-02-26 | |
| 13 | SUBSTANTIAL MODIFICATION | SM-12 | 2026-02-24 | Acceptable | 2026-03-06 | |
| 14 | SUBSTANTIAL MODIFICATION | SM-11 | 2026-02-27 | Acceptable | 2026-03-23 | |
| 15 | SUBSTANTIAL MODIFICATION | SM-14 | 2026-03-25 | Acceptable | 2026-05-08 | |
| 16 | SUBSTANTIAL MODIFICATION | SM-15 | 2026-03-26 | Acceptable | 2026-04-07 | |
| 17 | SUBSTANTIAL MODIFICATION | SM-13 | 2026-03-31 | Acceptable | 2026-05-08 | |
| 18 | SUBSTANTIAL MODIFICATION | SM-17 | 2026-04-27 | Germany | Acceptable | 2026-06-03 |
| 19 | SUBSTANTIAL MODIFICATION | SM-16 | 2026-05-06 | Acceptable | 2026-06-01 |